What we do Vikram Thermo manufactures and exports pharmaceutical excipients and polymers, specializing in film coating and sustained release formulations for the pharma industry. |
Founded in 1,984 |
Market share Asia's largest manufacturer for pharma coating polymers as of 2018, commanding strong presence in India and key export markets. |
Problem solved Provides advanced coating and polymer solutions enabling controlled drug release, taste masking, and moisture barriers for pharmaceutical formulations. |
Top clients or who we serve Serves pharmaceutical companies globally with B2B model, offering specialized excipients for drug coating and formulation. |
Key management Mr. Dhirajlal Karsandas Patel (Chairman & Managing Director), Dr. Dineshkumar H. Patel (Whole Time Director), Mr. Ankur D. Patel (Whole Time Director). |
Our journey and innovations Started with Diphenyl Oxide in 1984; commissioned cGMP facility in 2009; became Asia's largest pharma polymer maker by 2018; launched new polymers in 2022. |
Where we operate Primarily India with exports to global pharmaceutical markets across several countries. |
Top products or what we offer Methacrylic acid copolymers (Drugcoat series), Pharma Polymers (Drugpol series), Heat transfer fluid (Diphenyl Oxide). |
Top brands Drugcoat L 100 and variants: #1 in pharma coating polymers in Asia; Drugpol 940/934: key pharma polymers; Diphenyl Oxide: premier heat transfer fluid. |
Raw materials needed Methacrylic acid, acrylic copolymers, chemicals for polymer synthesis and heat transfer fluids. |
Raw materials supplier Main suppliers include regional chemical manufacturers and importers specialized in pharmaceutical-grade materials. |
Recurring vs cyclical contribution Majority of revenues are recurring through consistent demand from pharmaceutical manufacturing cycles. |
Our industry position Market leader in pharmaceutical excipients and polymers in India and Asia with scalable manufacturing facilities. |
Financial highlights Revenue Rs.126.23 Cr, PAT Rs.8.1 Cr for FY 2024-25; revenue grew over 24% year-on-year from previous year. |
Geographical revenue split India contributes about 69% of revenue; rest of the world accounts for 31%. |
Order book - |
Whats driving growth Strong R&D, expanded production capacity, global pharma demand, and product innovation driving revenue growth. |
Our future plans Focus on R&D investment, technology adoption, product portfolio enhancement, and expanding export markets. |
Our green promise Committed to energy conservation with ongoing exploration of alternative energy sources and process optimization. |
Our people and values Employs skilled workforce focusing on research innovation, ethics, and inclusive corporate culture. |
Key challenges ahead Managing risks from regulatory changes, market competition, raw material supply volatility, and maintaining growth momentum. |
Interesting facts First Indian manufacturer of Diphenyl Oxide; Asia's largest pharma polymer maker since 2018. |
Risks and strategy Risk from pharma industry regulation mitigated by product diversification; strategy emphasizes innovation and market expansion. |
